Netilmicin

Paul G. Auwaerter, M.D., Kathryn Dzintars, Pharm.D., BCPS

INDICATIONS

FDA

  • Not currently marketed or FDA-approved in the U.S.
  • Systemic Netromycin was discontinued from U.S. marketing, and its approval was formally withdrawn in 2000.

NON-FDA APPROVED USES

  • Complicated urinary tract infections
  • Septicemia in combination with a beta-lactam (generally not used as aminoglycoside monotherapy)
  • Skin and skin structure infections
  • Intra-abdominal infections (in combination)
  • Lower respiratory tract infections in combination with a beta-lactam (generally not used as aminoglycoside monotherapy)
  • Bacterial conjunctivitis and bacterial blepharitis (opth)

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: November 7, 2026